(Q45857818)

17 December 2017

title

Rituximab for adolescents with haemophilia and high titre inhibitors (English)

1 reference

17 December 2017

1 reference

1 reference

Fox RA

1

1 reference

17 December 2017

Neufeld EJ

series ordinal

2

1 reference

17 December 2017

Bennett CM

series ordinal

3

1 reference

17 December 2017

publication date

1 May 2006

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

218-222

1 reference

17 December 2017

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Inhibitors to clotting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Rituximab therapy for multisystem autoimmune diseases in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01215.X

10.1111/J.1365-2516.2006.01215.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017